Search Results - "Bonaca, Marc P."

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials by Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo H M, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John P H, Sabatine, Marc S

“…The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based…”
Get full text

Rivaroxaban in Peripheral Artery Disease after Revascularization by Bonaca, Marc P, Bauersachs, Rupert M, Anand, Sonia S, Debus, E. Sebastian, Nehler, Mark R, Patel, Manesh R, Fanelli, Fabrizio, Capell, Warren H, Diao, Lihong, Jaeger, Nicole, Hess, Connie N, Pap, Akos F, Kittelson, John M, Gudz, Ivan, Mátyás, Lajos, Krievins, Dainis K, Diaz, Rafael, Brodmann, Marianne, Muehlhofer, Eva, Haskell, Lloyd P, Berkowitz, Scott D, Hiatt, William R

“…Patients with peripheral artery disease who underwent revascularization were randomly assigned to receive rivaroxaban (2.5 mg twice daily) or placebo. All…”
Get full text

Pharmacological Treatment and Current Management of Peripheral Artery Disease by Bonaca, Marc P, Creager, Mark A

“…Patients with peripheral artery disease (PAD) are at heightened risk of both systemic cardiovascular adverse events, as well as limb-related morbidity. The…”
Get full text

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus by Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo H.M, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John P.H, Bonaca, Marc P, Ruff, Christian T, Desai, Akshay S, Goto, Shinya, Johansson, Peter A, Gause-Nilsson, Ingrid, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S, Wiviott, Stephen D

“…BACKGROUND:In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2…”
Get full text

Microvascular Disease, Peripheral Artery Disease, and Amputation by Beckman, Joshua A, Duncan, Meredith S, Damrauer, Scott M, Wells, Quinn S, Barnett, Joey V, Wasserman, David H, Bedimo, Roger J, Butt, Adeel A, Marconi, Vincent C, Sico, Jason J, Tindle, Hilary A, Bonaca, Marc P, Aday, Aaron W, Freiberg, Matthew S

“…BACKGROUND:The mechanism of adverse limb events associated with peripheral artery disease remains incompletely understood. We investigated whether…”
Get full text

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial by Wiviott, Stephen D., Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A., McGuire, Darren K., Wilding, John PH, Gause-Nilsson, Ingrid AM, Langkilde, Anna Maria, Johansson, Peter A., Sabatine, Marc S.

“…Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT-2) inhibitor that reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting…”
Get full text

DECLARE‐TIMI 58: Participants’ baseline characteristics by Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P., Cahn, Avivit, Kato, Eri T., Silverman, Michael G., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P. H., Gause‐Nilsson, Ingrid A. M., Langkilde, Anna M., Johansson, Peter A., Sabatine, Marc S., Wiviott, Stephen D.

“…Aim To describe the baseline characteristics of participants randomized in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE‐TIMI 58) trial, the…”
Get full text

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial by Storey, Robert F., MD, DM, Angiolillo, Dominick J., MD, Bonaca, Marc P., MD, MPH, Thomas, Mark R., MD, Judge, Heather M., PhD, Rollini, Fabiana, MD, Franchi, Francesco, MD, Ahsan, Arif J., MD, Bhatt, Deepak L., MD, MPH, Kuder, Julia F., MA, Steg, Philippe Gabriel, MD, Cohen, Marc, MD, Muthusamy, Rangasamy, MD, Braunwald, Eugene, MD, Sabatine, Marc S., MD, MPH

“…Abstract Background The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a…”
Get full text

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial by Scirica, Benjamin M, Dr, Bonaca, Marc P, MD, Braunwald, Eugene, Prof, De Ferrari, Gaetano M, MD, Isaza, Daniel, MD, Lewis, Basil S, Prof, Mehrhof, Felix, MD, Merlini, Piera A, Prof, Murphy, Sabina A, MPH, Sabatine, Marc S, MD, Tendera, Michal, Prof, Van de Werf, Frans, Prof, Wilcox, Robert, Prof, Morrow, David A, MD

“…Summary Background Vorapaxar inhibits platelet activation by antagonising thrombin-mediated activation of the protease-activated receptor 1 on human platelets…”
Get full text

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial by Hess, Connie N., Capell, Warren H., Bristow, Michael R., Ruf, Wolfram, Szarek, Michael, Morrow, David A., Nicolau, Jose C., Graybill, Christopher A., Marshall, Debra, Hsia, Judith, Bonaca, Marc P.

“…The interaction between thrombosis and inflammation appears central to COVID-19-associated coagulopathy and likely contributes to poor outcomes. Tissue factor…”
Get full text

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial by Bonaca, Marc P., MD, MPH, Bhatt, Deepak L., MD, MPH, Braunwald, Eugene, MD, Cohen, Marc, MD, Steg, Philippe Gabriel, MD, Storey, Robert F., MD, Held, Peter, MD, PhD, Jensen, Eva C., MD, PhD, Sabatine, Marc S., MD, MPH

“…Background P2Y12 receptor antagonist therapy is recommended in addition to ASA for up to 1 year after acute coronary syndrome to reduce ischemic events. In…”
Get full text

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial by Kohli, Payal, Bonaca, Marc P, Kakkar, Rahul, Kudinova, Anastacia Y, Scirica, Benjamin M, Sabatine, Marc S, Murphy, Sabina A, Braunwald, Eugene, Lee, Richard T, Morrow, David A

“…We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients with non-ST-elevation acute…”
Get full text

Impact of transitioning to virtual delivery of a cardiovascular health improvement program for Latinos during the COVID-19 pandemic by Iglesias, Amelia, Ambrose, Ashley, Coronel-Mockler, Stephanie, Kilbourn, Kristin, Bonaca, Marc P, Estacio, Raymond O, Krantz, Mori J

“…Abstract Background Community Heart Health Actions for Latinos at Risk (CHARLAR) is a promotora-led cardiovascular disease (CVD) risk-reduction program for…”
Get full text

Prognostic Performance of Multiple Biomarkers in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome by O’Malley, Ryan G., MD, Bonaca, Marc P., MD, Scirica, Benjamin M., MD, MPH, Murphy, Sabina A., MPH, Jarolim, Petr, MD, PhD, Sabatine, Marc S., MD, MPH, Braunwald, Eugene, MD, Morrow, David A., MD, MPH

“…Objectives The aim of this study was to assess the prognostic performance of C-terminal provasopressin (copeptin), midregional pro-adrenomedullin (MR-proADM),…”
Get full text

Addressing Knowledge Gaps in Patients With High-Risk Peripheral Artery Disease by Rogers, R. Kevin, Bonaca, Marc P.

Get full text

At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers by Humphreys, Devon P, Gavin, Kathleen M, Olds, Kaylan M, Bonaca, Marc P, Bauer, Timothy A

“…Diagnostic testing accessibility and asymptomatic transmission of SARS-CoV-2 present major challenges for curbing and preventing community prevalence of…”
Get full text

Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial by Yuan, Zhong, Levitan, Bennett, Deng, Hsiaowei, Szarek, Michael, Bauersachs, Rupert M, Berkowitz, Scott D, Haskell, Lloyd, Barnathan, Elliot S, Bonaca, Marc P

“…The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery…”
Get full text

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction by Magnani, Giulia, Ardissino, Diego, Im, KyungAh, Budaj, Andrzej, Storey, Robert F, Steg, P Gabriel, Bhatt, Deepak L, Cohen, Marc, Oude Ophius, Ton, Goudev, Assen, Parkhomenko, Alexander, Kamensky, Gabriel, Angiolillo, Dominick J, López-Sendón, José, Johanson, Per, Braunwald, Eugene, Sabatine, Marc S, Bonaca, Marc P

“…Background Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification of patients at lower bleeding…”
Get full text

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial by Morrow, David A., MD, MPH, Scirica, Benjamin M., MD, MPH, Fox, Keith A.A., MD, Berman, Gail, MD, Strony, John, MD, Veltri, Enrico, MD, Bonaca, Marc P., MD, Fish, Polly, BA, McCabe, Carolyn H., BS, Braunwald, Eugene, MD

“…Background Thrombin potently activates platelets via interaction with the protease-activated receptor 1. SCH 530348 is a novel antiplatelet agent that…”
Get full text

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial by Gencer, Baris, Li, Xinmin S, Gurmu, Yared, Bonaca, Marc P, Morrow, David A, Cohen, Marc, Bhatt, Deepak L, Steg, P Gabriel, Storey, Robert F, Johanson, Per, Wang, Zeneng, Hazen, Stanley L, Sabatine, Marc S

“…Background Trimethylamine N-oxide (TMAO) may have prothrombotic properties. We examined the association of TMAO quartiles with major adverse cardiovascular…”
Get full text